Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Kirin Co., Limited

Roussel Uclaf

Ichiro Miki

Akio Ishii

Akira Karasawa

Kazuhiro Kubo

Hiroyuki Obase

Etsuo Oshima

Fumio Suzuki

Kenji Ohmori

Shunji Ichikawa

Hiroaki Hayashi

Hidee Ishii

Yoshikazu Miwa

Etsuo Ohshima

Koji Suzuki

Koji Yanagawa

Motoo Yamasaki

Tatsuya Murakami

Katsuichi Shuto

Takeshi Kuroda

Hitoshi Arai

Haruhiko Manabe

So Ohta

Satoshi Nakanishi

Kimihisa Ueno

Shiro Shirakura

Tadafumi Tamura

Seiji Aratake

Kinya Yamashita

Takashi Kuwabara

Yoshiaki Masuda

Akira Tanaka

Tsutomu Matsumura

Mayumi Mukai

Motoki Miyama

Hiroshi Ishida

Masako Uchii

Katsuya Kobayashi

Noriko Sakurai

Toshio Suda

Obase Hiroyuki

Kubo Shizuoka

Toshiyuki Suzuwa

Yosuke Yamaura

Ari Kawabe

Takashi Sato

Shinya Fujii

Miho Iwase

The invention provides an agent for preventing or treating arthritis, a cartilage protecting agent, a joint destruction inhibitor and a synovial membrane growth inhibitor comprising an anti-FGF-8 neutralizing antibody as an active ingredient, as well as a diagnostic agent of arthritis comprising an anti-FGF-8 antibody as an active ingredient and a method for judging arthritis using the antibody.

Remedies for arthritis

The present invention provides branched polyalkylene glycols useful as a chemically modifying agent for physiologically active polypeptides, wherein two single-chain polyalkylene glycols are linked to a group having a cyclic structure other than a plane structure, and wherein a group having reactivity with an amino acid side chain, an N-terminal amino group or a C-terminal carboxyl group in a polypeptide or a group convertible into the group having reactivity is linked to the group having a structure other than a plane structure.

Branched polyalkylene glycols

[wherein m and n may be the same or different and each represents an integer of 1 to 3 wherein m+n is 4 or less; Rrepresents &#x2014;NRR(wherein Rand Rmay be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aralkyl or the like); Rrepresents the above Formula (II), Formula (IV) or the like; A represents a single bond, &#x2014;C(&#x2550;O)&#x2014;, &#x2014;SO&#x2014;, &#x2014;OC(&#x2550;O)&#x2014; or the like; and Rrepresents substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aralkyl or the like] Bicyclic pyrimidine derivatives represented by the above Formula (I), or quaternary ammonium salts thereof, or pharmaceutically acceptable salts thereof, or the like, are provided. These have anti-inflammatory activities or modulation activities on the functions of TARC and/or MDC and are useful for treating and/or preventing a disease which is related to T cells, such as an allergic disease, an autoimmune disease or transplant rejection.

Bicyclic pyrimidine derivatives

Oxygen-containing heterocyclic compounds

Quinoline derivative having serotonin-3 receptor antagonizing activity

Novel tricyclic compound represented by formula ##STR1## possess a TXA.sub.2 biosynthesis inhibiting activity and/or a TXA.sub.2 receptor antagonizing activity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.

Tricyclic compounds as TXA.sub.2 antagonists

Novel tricyclic compounds having a TXA.sub.2 antagonizing activity represented by formula (I): ##STR1## possess a potent antagonizing against thromboxane A.sub.2 and also an antiallergic and/or antihistaminic activity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.

Tricyclic thromboxane A.sub.2 antagonists

There is disclosed a heterocyclic compound represented by general formula: ##STR1## wherein R.sup.1 represents hydrogen, lower alkyl or aryl; R.sup.2 represents hydrogen, hydroxyl or lower alkyl; A represents CH or N; X represents --O-- or --NH--; R.sup.3 represents hydrogen, hydroxyl or lower alkyl; R.sup.4 represents lower alkyl; represents 0 or 1, or a pharmaceutically acceptable salt thereof.

Certain 2-oxo-quinoline carboxylates or corresponding carboxamides

Novel Tricyclic compound represented by formula ##STR1## possess a TXA.sub.2 biosynthesis inhibiting act and/or a TXA.sub.2 receptor antagonizing activity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.

Disclosed is a thienopyridine derivative represented by formula (I): ##STR1## wherein one of A and B represents --S-- and the other represents --CH.dbd.; X represents --O-- or --NH--; R.sup.1 represents hydrogen or lower alkyl; R.sup.2 represents lower alkyl; and n represents 0 or 1; or a pharmaceutically acceptable salt thereof.

Thienopyridine derivatives

Novel tricyclic compounds having a TXA.sub.2 antagonizing activity represented by formula (I): ##STR1## possess a potent antagonizing action against thromboxane A.sub.2 and also an antiallergic and/or antihistaminic acitvity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.

Novel tricyclic compound represented by formula (I): ##STR1## possess a TXA.sub.2 biosynthesis inhibiting activity and/or a TXA.sub.2 receptor antagonizing activity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.

Novel tricyclic compounds having a TXA.sub.2 -antagonizing activity represented by formul (I): ##STR1## which strongly antagonize an action of thromboxane A.sub.2 and are expected to have preventive and therapeutic effects on ischemica diseases, cerebro-vascular diseases, etc.

Tricyclic compounds

Novel tricyclic compounds having a TXA.sub.2 -antagonizing activity represented by formula (I): ##STR1## which strongly antagonize an action of thromboxane A.sub.2 and are expected to have preventive and therapeutic effects on ischemica diseases, cerebro-vascular diseases, etc.

Tricyclic compounds and TXA.sub.2 antagonistic compositions thereof

Growing community of inventors

Shizuoka, Japan

Ichiro Miki